Search the Newsreel

Stagwell’s 10 New Employees Receive Stock Units Vesting Over 3 Years

Stagwell (NASDAQ: STGW) has granted a total of 77,717 restricted stock units (RSUs) to 10 new employees, effective August 6, 2026. These RSUs, convertible into Class A common shares, will vest over two and three years, with accelerated vesting provisions for certain termination events. …

STAG INDUSTRIAL RECEIVES 'BBB' INVESTMENT GRADE RATING FROM S&P GLOBAL RATINGS

STAG Industrial, Inc. has received a 'BBB' investment grade rating with a stable outlook from S&P Global Ratings, adding to existing investment grade ratings from Fitch Ratings and Moody's Ratings. This new rating is expected to broaden the company's access to debt sources and …

Vistagen's second fasedienol dose showed no new safety findings

Vistagen (Nasdaq: VTGN) announced topline results from an exploratory Phase 2 study of intranasal fasedienol for social anxiety disorder, showing repeat dosing was safe and well-tolerated with no new safety findings. While overall statistical significance was not met for primary efficacy endpoints, nominally significant …

Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder

Vistagen (Nasdaq: VTGN) announced topline results from an exploratory Phase 2 repeat dose study of fasedienol nasal spray for social anxiety disorder. The study showed favorable safety and tolerability, with efficacy signals observed across primary and secondary endpoints, particularly in patients with very severe …

Vistagen Therapeutics (NASDAQ: VTGN) granted 180-day Nasdaq bid-price extension

Vistagen Therapeutics (NASDAQ: VTGN) has received a 180-day extension from Nasdaq, until February 1, 2027, to regain compliance with the $1.00 per share minimum bid price requirement. The company's common stock listing remains effective, and Vistagen intends to cure the deficiency within this period …

Vistagen Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard

Vistagen Therapeutics (VTGN) announced it received an extension from Nasdaq until February 1, 2027, to meet the $1.00 minimum bid price requirement. The company's listing remains active during this period, but failure to comply could lead to delisting. This information is based on an …

STAG Industrial (STAG) Earnings And Dividend Put Valuation Back In Focus

Vistagen Therapeutics, Inc. Stockholders with Large Losses in VTG

Robbins LLP is reminding investors that a class action lawsuit has been filed against Vistagen Therapeutics, Inc. (NASDAQ: VTGN) on behalf of stockholders who purchased shares between April 1, 2024, and December 16, 2025. The lawsuit alleges that Vistagen misled investors regarding the viability …

Vistagen Therapeutics Inc expected to post a loss of 36 cents a share - Earnings Preview

Vistagen Therapeutics Inc is projected to report a loss of 36 cents per share, according to an earnings preview. The article indicates that this information is sourced from Refinitiv. Readers are prompted to access the full article through a paid subscription on TradingView.

SRX Global acquires stake in Vistagen Therapeutics

SRX Global has acquired a minority equity stake in Vistagen Therapeutics, a Nasdaq-listed biotech company. The investment targets Vistagen's late-stage neuroscience pipeline, specifically its intranasal "pherine" product candidates. SRX Global believes Vistagen shares are undervalued and plans to engage with management and the board …

Is STAG Industrial's (STAG) Steady Dividend Masking Subtler Profit Pressures?

STAG Industrial reported mixed Q2 2026 results with increased revenue and quarterly net income but a decline in net income for the first half of the year. Despite these profit pressures and concerns about interest coverage, the company maintained its Q3 2026 dividend of …

Stagwell (NASDAQ: STGW) boosts CEO pay and awards 2M cash SARs

Stagwell Inc. has extended CEO Mark Penn's employment through July 31, 2029, and significantly updated his compensation package. This includes an increase in his annual base salary to $1.4 million, a one-time cash bonus of $581,667, and the grant of 2 million cash-settled stock …

Glenmede Trust Co. NA Reduces Stock Position in Stag Industrial, Inc. $STAG

Glenmede Trust Co. NA decreased its stake in Stag Industrial, Inc. by 8.1% in the first quarter, selling 30,362 shares but still holding 345,325 shares valued at $12.45 million. Other institutional investors like Norges Bank and UBS AM significantly increased their positions. Analyst ratings …

Ncs Multistage Holdings Inc (NCSM) Q4 2023 Earnings Report - Results, Call & Slides

NCS Multistage Holdings Inc. (NCSM) reported its Q4 2023 earnings, missing both EPS and revenue expectations. The company posted an actual EPS of -$0.36 against a consensus of $1.18 and revenue of $35.25 million, missing the expected $39.70 million. Revenue also saw a year-over-year …

NCS Multistage Holdings (NCSM) Stock Rises Despite Sharp Quarterly Profit Reversal

NCS Multistage Holdings (NCSM) stock rose by 3.5% despite a significant quarterly profit reversal, swinging from a profit to a US$4.6 million loss. While revenue increased year-over-year, the sharp drop in EPS and net income raises concerns about earnings volatility. The market appears to …

Stag Industrial Earnings Call Highlights Resilient Momentum

Stag Industrial's Q2 earnings call revealed an optimistic outlook for the industrial real estate market, citing strong tenant demand, robust leasing spreads, and steady FFO growth. The company reported a 3.2% year-over-year increase in core FFO per share and raised its 2026 guidance, supported …

Edgestream Partners L.P. Trims Stock Holdings in Stag Industrial, Inc. $STAG

Edgestream Partners L.P. significantly reduced its stake in Stag Industrial, Inc. by 43.1% in the first quarter, selling over 65,000 shares but retaining 86,216 shares valued at $3.1 million. Despite institutional investors owning a large portion of the REIT, analyst sentiment is mixed, with …

NCS Multistage: Q2 Earnings Snapshot

This article provides an earnings snapshot for NCS Multistage's Q2 results. No specific financial details are available in the provided content, but it indicates the publication of their second-quarter performance.

Stagwell (STGW) Stock Stalls Despite Record Growth And Margin Gains

Stagwell (STGW) stock saw a muted reaction despite reporting record Q2 revenue of US$786.3m and double-digit organic growth. While the company showed improved adjusted EBITDA margins and strong new business wins, concerns remain regarding continued net losses, high leverage, and slow growth in core …

Stagwell (STGW) Is Up 13.9% After Raising EPS Outlook On Stronger Organic And AI-Driven Growth

In the second quarter of 2026, Stagwell Inc. reported higher sales of US$786.31 million year on year but a wider net loss, while management outlined plans for a balanced mix of organic growth, selective acquisitions in the second half, stock buybacks, and debt reduction. …

Form 4 VistaGen Therapeutics Inc For: 31 July By Investing.com

This article reports on a Form 4 filing for VistaGen Therapeutics Inc. as of July 31. Form 4s disclose transactions made by company insiders and are important for investors to track. The article is very brief, serving primarily as an announcement of the filing …

Press Release: Vistagen Appoints Douglas J. Williamson to Its Board of Directors

Vistagen Therapeutics, Inc. has announced the appointment of Douglas J. Williamson, M.D. to its Board of Directors. Dr. Williamson brings extensive experience in psychiatric drug development and will also serve on the Nominating & Corporate Governance Committee. This appointment expands Vistagen's Board to eight …

STGW (STGW) files Form 144 for sale of 62,000 Class A shares

Stagwell Inc. (STGW) has filed a Form 144 indicating a proposed sale of 62,000 Class A common shares with an aggregate market value of $526,380.00. The shares, acquired through equity compensation from a stock appreciation right exercise and restricted stock award vesting, are to …

NCS Multistage Holdings, Inc. 2Q 2026: Revenue $38.36M, EPS ($1.71) — 10-Q Summary

NCS Multistage Holdings, Inc. reported its second-quarter 2026 results, showing a 5.2% year-over-year revenue increase to $38.36M, alongside a net loss of $4.61M and diluted EPS of ($1.71). The company experienced modest top-line growth driven by services and product sales, offset by costs related …

NCS Multistage (NASDAQ: NCSM) posts Q2 loss as Weatherford buyout advances

NCS Multistage Holdings, Inc. (NCSM) reported a Q2 2026 net loss of $4.6 million, a swing from profit in the prior year, despite a slight revenue increase to $38.4 million. This loss was primarily due to higher SG&A expenses, including $2.3 million in costs …

NCS Multistage Holdings Q2 Results: EPS Misses, Sales Beat

NCS Multistage Holdings reported a 5% year-over-year revenue increase to $38.4 million in Q2 2026, primarily driven by growth in its U.S. Repeat Precision segment. Despite this top-line growth, the company's net loss widened to $(4.6) million from a prior-year profit of $0.9 million, …

Vistagen Therapeutics (NASDAQ: VTGN) sets 2026 virtual meeting, director slate and pay vote

Vistagen Therapeutics (NASDAQ: VTGN) has announced its 2026 annual virtual meeting for September 10, 2026. Stockholders will vote on the election of four directors, a non-binding advisory vote on Named Executive Officer compensation, and the ratification of KPMG LLP as the independent auditor. The …

Vistagen Therapeutics Inc (VTGN) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Vistagen Therapeutics Inc (VTGN), ranking it 315 out of 385 in the Biotechnology & Medical Research industry with a score of 1.25. It highlights the company's beta value of 0.31, indicating lower volatility compared to the S&P …

Stag Industrial, Inc. Revenue Breakdown – NYSE:STAG

This article provides a breakdown of Stag Industrial, Inc.'s revenue for the last year, highlighting its top-performing segment and geographical contribution. The company generated $843.01 million USD, with Fixed Lease Payments being the primary segment at $640.88 million USD, and the United States contributing …

Vistagen Therapeutics (Nasdaq: VTGN) names Douglas J. Williamson to board

Vistagen Therapeutics, Inc. (Nasdaq: VTGN) has appointed Douglas J. Williamson, M.D. to its Board of Directors, effective July 29, 2026. Dr. Williamson, who has nearly three decades of experience in neuroscience drug development, received stock options and will be compensated under the company's Director …

VistaGen files Form 3 as director Douglas J. Williamson reports no beneficial ownership

VistaGen Therapeutics director Douglas J. Williamson has filed an initial Form 3, indicating no beneficial ownership. This filing was made on July 31, 2026, and the information was originally published via EDGAR by VistaGen Therapeutics Inc. The news brief is an AI-generated content for …

Garden Stage FY26 net loss widens to US$13.84 million; revenue rises 33.2% to US$7.28 million

Garden Stage reported a significant widening of its net loss to US$13.84 million in fiscal 2026, despite a 33.2% increase in revenue to US$7.28 million. The company saw professional fees and brokerage fees rise, while introducing and referral income decreased. Cash and restricted cash …

Vistagen adds board director with nearly three decades in neuroscience drug development

Vistagen (Nasdaq: VTGN) has appointed Douglas J. Williamson, MD, to its Board of Directors, leveraging his nearly three decades of experience in neuroscience drug development, clinical research, and regulatory strategy. Dr. Williamson's background includes leadership roles at several biopharmaceutical companies and contributions to the …

Norris Financial Group LLC Takes Position in Stag Industrial, Inc. $STAG

Norris Financial Group LLC has acquired a new position in Stag Industrial, Inc. (NYSE:STAG), purchasing 53,780 shares valued at approximately $1.94 million during the first quarter. Institutional investors and hedge funds collectively own 88.67% of the REIT, which recently reported an 8.1% year-over-year revenue …

Garden Stage (Nasdaq: GSIW) flags China oversight and HFCAA risk

NCS Multistage (NASDAQ:NCSM) Issues Quarterly Earnings Results